AFM 13

Drug Profile

AFM 13

Alternative Names: AFM-13; Anti CD30 x anti CD16; Anti-CD30 anti-CD16A antibody - Affimed Therapeutics; TandAb AFM13

Latest Information Update: 07 Apr 2017

Price : $50

At a glance

  • Originator Affimed Therapeutics
  • Developer Affimed Therapeutics; Merck AG; The Leukemia & Lymphoma Society; University of Cologne; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action CD30 antigen modulators; Fc gamma receptor IIIA modulators; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hodgkin's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hodgkin's disease
  • Preclinical Non-Hodgkin's lymphoma

Most Recent Events

  • 07 Apr 2017 Preclinical trials in Hodgkin's disease (in combination with NK cells) in USA (IV) (Affimed Therapeutics pipeline, April 2017)
  • 04 Jan 2017 Affimed and University of Texas M. D. Anderson Cancer Center enter into a strategic collaboration for clinical development and commercialisation of AFM 13 in combination with natural killer cell product
  • 04 Jan 2017 University of Texas MD Anderson Cancer Center and Affimed plan a phase I trial for Hodgkin's lymphoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top